SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Neal JW. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist. 2010; 15: 3-5.
  • 2
    Stinchcombe TE, Grilley-Olson JE, Socinski MA. If histology matters. J Clin Oncol. 2010; 28: 1810-1812.
  • 3
    Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M. A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009; 17: 206-218.
  • 4
    West H, Harpole D, Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest. 2009; 136: 1112-1118.
  • 5
    Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004.
  • 6
    Rosai J. Why microscopy will remain a cornerstone of surgical pathology. Lab Invest. 2007; 87: 403-408.
  • 7
    Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007; 15: 415-420.
  • 8
    Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008; 132: 384-396.
  • 9
    Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol. 2009; 22: 1032-1043.
  • 10
    Kim DH, Kwon MS. Role of fine needle aspiration cytology, cell block preparation and CD63, P63 and CD56 immunostaining in classifying the specific tumor type of the lung. Acta Cytol. 2010; 54: 55-59.
  • 11
    Vazquez MF, Koizumi JH, Henschke CI, Yankelevitz DF. Reliability of cytologic diagnosis of early lung cancer. Cancer. 2007; 111: 252-258.
  • 12
    Carvalho L. Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol. 2009; 15: 1101-1119.
  • 13
    Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009; 37: 178-183.
  • 14
    Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol. 2000; 53: 537-540.
  • 15
    Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR- mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol. 2008; 214: 347-356.
  • 16
    Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009; 22: 709-717.
  • 17
    Pelosi G, Sonzogni A, Papotti M, Righi L, Rossi G, Viale G. Different prevalence of transactivating (TA) p63 and non-TA isoforms in pulmonary adenocarcinomas: a useful diagnostic tool. Mod Pathol. 2010; 23 ( suppl 1): 411A-412A.
  • 18
    Rossi G, Papotti M, Barbareschi M, Graziano P, Pelosi G. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol. 2009; 27( 28): e141-142.
  • 19
    Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010; 5: 442-447.
  • 20
    Kim S, Owens CL. Analysis of ThinPrep cytology in establishing the diagnosis of small cell carcinoma of lung. Cancer Cytopathol. 2009; 117: 51-56.
  • 21
    Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol. 2010; 18: 142-149.
  • 22
    Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000; 13: 238-242.
  • 23
    Pelosi G, Pasini F, Olsen Stenholm C, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol. 2002; 198: 100-109.
  • 24
    Candi E, Dinsdale D, Rufini A, et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle. 2007; 6: 274-285.
  • 25
    Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas [published online ahead of print September 9, 2010]. Cancer Cytopathol. doi: 10.1002/cncy.20108.
  • 26
    Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006; 17: 1818-1825.
  • 27
    Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006; 107: 1589-1596.
  • 28
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.